Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00282295 · ClinicalTrials.gov registry record · Phase 4
US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease
A Phase 4 study of Diphtheria and Tetanus, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,344
- Enrollment target
- 20
- Study locations
NCT00282295 is a Phase 4 study of Diphtheria and Tetanus that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,344 participants, below the 1,777-participant average among 15 other Diphtheria trials with a reported enrollment target (24% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT00282295, a Phase 4 study of Diphtheria and Tetanus, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,344 participants
- Enrollment target
- 20
- Study locations
Study Summary
New immunization recommendations in the US include vaccination of adolescents against pertussis and meningococcal disease. The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention recommends that Tdap (Tetanus Toxoid, Reduced Diphtheria Toxoid And Acellular Pertussis Vaccine Adsorbed) and MCV4 (Meningococcal conjugate vaccine against serotypes A, C, Y and W-135) vaccines be administered to adolescents at the same office visit if vaccination with both vaccines is indicated. Therefore, this study is designed to evaluate the safety and immunogenicity of a booster vaccination with Boostrix co-administered with Menactra as compared to the administration of either vaccine alone in healthy adolescents 11 - 18 years of age.
Conditions Studied
Interventions
- BIOLOGICAL Boostrix®
- BIOLOGICAL Menactra™
Study Locations (20)
Pennsylvania
- GSK Investigational Site - Erie
- GSK Investigational Site - Erie
- GSK Investigational Site - Greenville
- GSK Investigational Site - Philadelphia
- GSK Investigational Site - Pittsburgh
- GSK Investigational Site - Pittsburgh
Maryland
- GSK Investigational Site - Annapolis
- GSK Investigational Site - Frederick
New York
- GSK Investigational Site - Pittsford
- GSK Investigational Site - Rochester
Ohio
- GSK Investigational Site - Akron
- GSK Investigational Site - University Heights
Arizona
- GSK Investigational Site - Chandler
Arkansas
- GSK Investigational Site - Little Rock
California
- GSK Investigational Site - Fountain Valley
Colorado
- GSK Investigational Site - Golden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,344 participants |
| Start Date | 2006-01-25 |
| Est. Completion | 2006-08-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00282295
The ClinicalTrials.gov registry entry for NCT00282295 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,344 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,777-participant average among 15 other Diphtheria trials with a reported enrollment target (24% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Diphtheria appearing as the primary indexed condition, and to 2 interventions - of which Boostrix® is the first listed.
NCT00282295 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Pennsylvania, Maryland, New York.
Frequently Asked Questions
What is clinical trial NCT00282295 about?
NCT00282295 is a clinical study titled "US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease". New immunization recommendations in the US include vaccination of adolescents against pertussis and meningococcal disease. The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention recommends that Tdap (Tetanus Toxoid, Reduced Diphtheria Toxoid And Acellular ...
What is the current status of trial NCT00282295?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,344 participants. The study started on 2006-01-25. Estimated completion is 2006-08-08.
What conditions does trial NCT00282295 study?
This clinical trial studies the following conditions: Diphtheria, Tetanus, Acellular Pertussis.
What interventions are being tested in trial NCT00282295?
The interventions under investigation include: Boostrix® (BIOLOGICAL), Menactra™ (BIOLOGICAL).
Who is sponsoring clinical trial NCT00282295?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00282295 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diphtheria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PFAS Exposure and Immune Response to Vaccination in Adults
COMPLETED · Phase 4
-
Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®
COMPLETED · Phase 4
-
Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents
COMPLETED · Phase 4
-
Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™
COMPLETED · Phase 4
-
Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine
COMPLETED · Phase 4
-
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.